Predictive Oncology Inc. (POAI)
NASDAQ: POAI · Real-Time Price · USD
0.754
+0.034 (4.76%)
Nov 25, 2024, 4:00 PM EST - Market closed
Predictive Oncology Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Predictive Oncology.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for POAI is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 0 |
Buy | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 1 |
Sell | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 15, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +297.72% | Aug 19, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $100 | Strong Buy | Initiates | $100 | +13,157.32% | Jun 30, 2021 |
Financial Forecast
Revenue This Year
1.42M
from 1.78M
Decreased by -20.12%
Revenue Next Year
9.52M
from 1.42M
Increased by 569.48%
EPS This Year
-2.12
from -3.48
EPS Next Year
-0.16
from -2.12
Revenue Forecast
Revenue | 2024 | 2025 | 2026 |
---|---|---|---|
High | 1.5M | 9.8M | 16.2M |
Avg | 1.4M | 9.5M | 15.8M |
Low | 1.4M | 9.1M | 15.1M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | -17.8% | 589.2% | 70.4% |
Avg | -20.1% | 569.5% | 65.5% |
Low | -23.3% | 543.2% | 59.0% |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | -2.18 | -0.17 | 0.08 |
Avg | -2.12 | -0.16 | 0.08 |
Low | -2.04 | -0.16 | 0.08 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.